Soligenix Inc (SNGX)
NASDAQ:SNGX
Want to see SNGX full AI Analyst Report?
Top Page
Soligenix
(NASDAQ:SNGX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.41
▼(-71.46% Downside)
Action:Reiterated
Date:06/13/26
The score is driven primarily by weak financial performance (no revenue, persistent losses, and significant cash burn), reinforced by bearish technicals (price below major moving averages with negative MACD). Corporate events add downside risk due to the halted HyBryte program and Nasdaq bid-price compliance issue, while valuation metrics provide limited support given negative earnings and no dividend data.
Positive Factors
Pipeline refocus to orphan asset
Shifting resources toward an orphan-designated program (dusquetide for Behçet’s) is a durable strategic move: orphan indications often benefit from accelerated pathways, smaller trial sizes, and premium pricing potential, improving odds of commercial viability versus broad indications over the medium term.
Negative Factors
Zero revenue and heavy cash burn
Persistent, sizable operating losses and matching negative free cash flow create an ongoing funding requirement. Without commercial revenue, the company must repeatedly access capital markets or grants, diluting shareholders or risking program delays—an enduring constraint on strategy and runway.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline refocus to orphan asset
Shifting resources toward an orphan-designated program (dusquetide for Behçet’s) is a durable strategic move: orphan indications often benefit from accelerated pathways, smaller trial sizes, and premium pricing potential, improving odds of commercial viability versus broad indications over the medium term.
Read all positive factors
Soligenix (SNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.92M
Dividend YieldN/A
Average Volume (3M)14.44M
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue GrowthN/A
EPS Growth54.48%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding14,824,174
10 Day Avg. Volume2,492,628
30 Day Avg. Volume14,436,977
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit741.41
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$1.50Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Soligenix Business Overview & Revenue Model
Company Description
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two mai...
How the Company Makes Money
Soligenix generates revenue primarily through (1) government and nongovernment research and development funding and (2) collaborations and related payments tied to its development programs. A material component of its historical revenue has come f...
Soligenix Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
36
Negative
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 250.00K | 33.35K |
| Gross Profit | 0.00 | -119.37K | -742.05K | -300.82K | -695.29K |
| EBITDA | -11.58M | -9.46M | -7.67M | -14.11M | -12.48M |
| Net Income | -11.08M | -8.27M | -6.14M | -13.80M | -12.55M |
Balance Sheet | |||||
| Total Assets | 9.24M | 8.97M | 9.80M | 14.28M | 26.87M |
| Cash, Cash Equivalents and Short-Term Investments | 7.94M | 7.82M | 8.45M | 13.36M | 26.04M |
| Total Debt | 358.14K | 1.48M | 3.49M | 10.24M | 9.96M |
| Total Liabilities | 3.94M | 4.85M | 7.27M | 16.75M | 16.15M |
| Stockholders Equity | 5.29M | 4.12M | 2.52M | -2.47M | 10.72M |
Cash Flow | |||||
| Free Cash Flow | -10.27M | -8.40M | -8.60M | -12.66M | -11.75M |
| Operating Cash Flow | -10.27M | -8.40M | -8.60M | -12.65M | -11.74M |
| Investing Cash Flow | -5.88K | 0.00 | 0.00 | -13.07K | -11.79K |
| Financing Cash Flow | 10.39M | 7.76M | 3.66M | 76.82K | 19.06M |
Soligenix Technical Analysis
Negative
1.44
Price Trends
0.66
Negative
0.92
Negative
1.28
Negative
Market Momentum
-0.06
Positive
39.98
Neutral
4.26
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Negative. The current price of 1.44 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.66, and above the 200-day MA of 1.28, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 39.98 is Neutral, neither overbought nor oversold. The STOCH value of 4.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNGX.
Soligenix Risk Analysis
Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soligenix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.18M | -1.63 | -22.03% | ― | -93.71% | 23.89% | |
44 Neutral | $15.60M | -0.79 | -119.35% | ― | -82.95% | 56.35% | |
41 Neutral | $5.92M | -0.37 | -246.04% | ― | ― | 54.48% | |
41 Neutral | $6.50M | -762.85 | ― | ― | ― | ― | |
41 Neutral | $6.98M | -0.13 | -709.51% | ― | -84.76% | 79.01% |
* Healthcare Sector Average
SNGX
Soligenix
0.40
-1.30
-76.53%
BLRX
Bioline RX Ltd Sponsored ADR
3.16
-1.08
-25.47%
CANF
Can-Fite BioPharma
2.98
-18.12
-85.88%
GOVX
GeoVax Labs
1.34
-22.26
-94.32%
AIMD
Ainos
1.83
-0.70
-27.67%
Soligenix Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy
Negative
Jun 12, 2026
On June 10, 2026, Soligenix received notice from Nasdaq that its shares no longer met the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, triggering a 180-day compliance period through December 7, 2026. Whil...
Private Placements and FinancingRegulatory Filings and Compliance
Soligenix Expands At-The-Market Equity Financing Capacity
Neutral
May 28, 2026
On May 28, 2026, Soligenix, Inc. filed a prospectus supplement to increase the maximum aggregate amount of common stock it may issue under its existing At Market Issuance Sales Agreement with Rodman Renshaw LLC by an additional $2,956,000, after ...
Business Operations and StrategyM&A TransactionsProduct-Related Announcements
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
Negative
Apr 28, 2026
On April 28, 2026, Soligenix reported interim results from its pivotal Phase 3 FLASH2 trial of HyBryte in CTCL, with an independent Data Monitoring Committee recommending the study be halted for futility after 18 weeks of treatment failed to repro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.